Document is current
Any future updates will be listed below
-
Authors
Rasmussen, Martin
Fredsøe, Jacob https://orcid.org/0000-0002-7319-2467
Tin, Amy L. https://orcid.org/0000-0002-8005-0694
Vickers, Andrew J.
Ulhøi, Benedicte
Borre, Michael
Eastham, James
Ehdaie, Behfar
Guillonneau, Bertrand
Laudone, Vincent
Scardino, Peter T.
Touijer, Karim
Sørensen, Karina D. https://orcid.org/0000-0002-4902-5490
Lilja, Hans https://orcid.org/0000-0001-5871-7846
- License Information
-
More Information
Article History
Received: 17 June 2021
Revised: 18 November 2021
Accepted: 1 December 2021
First Online: 13 December 2021
Competing interests
: HL holds patents on assays for intact PSA. AJV and HL are named on a patent for a statistical method to detect prostate cancer (the 4KScore test) that has been commercialised by OPKO Health. AJV and HL receive royalties from sales of the test. HL has stock and AJV has stock options in OPKO Health. KDS and JF are co-inventors on issued patents for epigenetic and microRNA biomarkers for prostate cancer, owned by Aarhus University and licensed to Qiagen.
: Ethical approval was obtained from the MSKCC IRB and The Central Denmark Region Committees on Health Research Ethics. Consent was received from all participants. The study was performed in accordance with the Declaration of Helsinki.
